How many institutional investors hold RARE?

3 tracked institutional investors disclosed a position in RARE (ULTRAGENYX PHARMACEUTICAL IN) in their most recent 13F filing.

Who is the largest institutional holder of RARE?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in RARE, valued at $61M.

Did institutional ownership of RARE increase or decrease?

Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited RARE.

Where does this RARE ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

RARE — ULTRAGENYX PHARMACEUTICAL IN

Name: ULTRAGENYX PHARMACEUTICAL IN (RARE) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About ULTRAGENYX PHARMACEUTICAL IN (RARE)

ULTRAGENYX PHARMACEUTICAL IN (RARE) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $61M. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in RARE

/100

Mixed Activity

Added / Increased0

Reduced0

Exited0

No recent activity recorded.

Crowded Trade Score™

How many top investors track RARE

/100

Emerging Interest

3investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

RARE Ownership Composition

How ULTRAGENYX PHARMACEUTICAL IN is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

82% of tracked value

Institutions

tracked investors

Total Reported

$105.5M

combined 13F value

Other82.3%
Hedge Funds17.7%

Other(2)

82.3%

Hedge Funds(1)

17.7%

Tracked investors reporting RARE

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	2.4M	$49.7M	0.01%	Mar 31, 2026
Izzy Englander	Millennium Management	1.8M	$37.1M	0.02%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	893.3K	$18.7M	0.02%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
2.4M
Value
$49.7M
% Portfolio
0.01%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
1.8M
Value
$37.1M
% Portfolio
0.02%
Steve CohenMar 31, 2026
Point72 Asset Management
Shares
893.3K
Value
$18.7M
% Portfolio
0.02%

Recent activity

Investor	Action	Δ %	Current value	Filing date
No recent activity.

No recent activity.

Frequently asked questions

How many institutional investors hold RARE?: 3 tracked institutional investors disclosed a position in RARE (ULTRAGENYX PHARMACEUTICAL IN) in their most recent 13F filing.
Who is the largest institutional holder of RARE?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in RARE, valued at $61M.
Did institutional ownership of RARE increase or decrease?: Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited RARE.
Where does this RARE ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.